- JP-listed companies
- Linical Co., Ltd.
- Income statement
Linical Co., Ltd. (2183) Income statement
Market cap
¥5.1B
P/E ratio
25.9x
Linical helps pharmaceutical companies develop and launch new drugs by providing clinical trial services, post-market safety monitoring, and drug discovery support.
| 2012/03 | 2013/03 | 2014/03 | 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 3,110 | 3,599 | 3,722 | 4,872 | 7,667 | 8,356 | 9,113 | 11,313 | 10,935 | 10,279 | 11,555 | 12,517 | 12,308 | 10,437 | 8,665 |
| Revenue growth (%) | - | ||||||||||||||
| Cost of revenue | - | - | - | 3,084 | 4,213 | 4,688 | 5,580 | 7,500 | 7,405 | 7,512 | 7,944 | 8,355 | 8,530 | 8,061 | 7,542 |
| Gross profit | - | - | - | 1,788 | 3,454 | 3,668 | 3,533 | 3,813 | 3,531 | 2,768 | 3,612 | 4,162 | 3,778 | 2,376 | 1,124 |
| Gross margin (%) | - | - | - | ||||||||||||
| Operating margin (%) | - | - | - | ||||||||||||
| Operating expenses | - | - | - | 911 | 1,442 | 1,539 | 1,687 | 2,600 | 2,525 | 2,314 | 2,526 | 2,905 | 3,053 | 2,959 | 3,197 |
| Operating income | - | - | - | 877 | 2,012 | 2,129 | 1,847 | 1,213 | 1,005 | 453 | 1,086 | 1,257 | 726 | -583 | -2,073 |
| Income before tax | 724 | 998 | 704 | 841 | 1,986 | 2,077 | 1,826 | 1,253 | 918 | 589 | 1,184 | 1,283 | 790 | -499 | -2,023 |
| Pretax margin (%) | 23.3 | 27.7 | 18.9 | 17.3 | 25.9 | 24.9 | 20 | 11.1 | 8.4 | 5.7 | 10.2 | 10.3 | 6.4 | -4.8 | -23.3 |
| Provision for income taxes | - | - | - | 298 | 655 | 563 | 530 | 596 | 325 | -181 | 241 | 374 | 322 | 114 | 316 |
| Effective tax rate (%) | - | - | - | ||||||||||||
| Net income | 435 | 620 | 447 | 437 | 1,331 | 1,448 | 1,296 | 568 | 483 | 540 | 790 | 1,004 | 338 | -539 | -2,238 |
| Earnings per share | 18.61 | 27.06 | 19.71 | 19.18 | 58.4 | 63.59 | 57.02 | 25.09 | 21.38 | 23.91 | 35 | 44.47 | 14.98 | -23.87 | -147.41 |
| Dividend per share | - | - | - | - | - | - | - | - | 14 | 14 | 14 | 14 | 15 | 16 | 8 |